We determined the impact of HER2 signaling on two proangiogenic factors, vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8), and on an antiangiogenic factor, thrombospondin-1 (TSP-1). Re-expression of HER2 in MCF-7 and T-47D breast cancer cells that endogenously express low levels of HER2 resulted in elevated expression of VEGF and IL-8 and decreased expression of TSP-1. Inhibition of HER2 with a humanized anti-HER2 antibody (trastuzumab, or Herceptin s ) or a retrovirus-mediated small interfering RNA against HER2 (siHER2) decreased VEGF and IL-8 expression, but increased TSP-1 expression in BT474 breast cancer cells that express high levels of HER2. These in vitro results were further evaluated by treatment of BT474 xenografts in immunosuppressed mice with trastuzumab. Trastuzumab inhibited growth of BT474 xenografts and decreased microvascular density associated with downregulation of VEGF and IL-8 and with upregulation of TSP-1 expression. Inhibiting the PI3K-AKT pathway decreased VEGF and IL-8 expression. AKT1 overexpession increased VEGF and IL-8 expression, but did not increase TSP-1 expression. A p38 kinase inhibitor, SB203580, instead blocked TSP-1 expression and a p38 activator, MKK6, increased TSP-1 expression. Trastuzumab stimulated sustained p38 activation and SB203580 attenuated the TSP-1 upregulation induced by trastuzumab. HER2 signaling therefore influences the equilibrium between pro-and antiangiogenic factors via distinct signaling pathways. Trastuzumab inhibits angiogenesis and tumor growth, at least in part, through activation of the HER2-p38-TSP-1 pathway and inhibition of the HER2-PI3K-AKT-VEGF/IL-8 pathway.
Introduction
The human epidermal growth factor receptor 2 (HER2, also known as ErbB-2 or c-neu) plays a critical role in epidermal growth factor receptor (EGFR) family signaling Holbro and Hynes, 2004; Marmor et al., 2004) . HER2 is amplified and/or overexpressed in about 20-30% of cases of human breast cancer. HER2 overexpression correlates with large tumor size, tumor spread to lymph nodes, high grade, high percentage of S phase cells, aneuploidy, higher metastatic potential, and decreased survival, all consistent with an increase in the growth and metastatic potential of cancer cells (Yu and Hung, 2000) . Blocking HER2 signaling arrests cancer cells in the G1 phase of the cell cycle and inhibits the growth of xenografts of tumors that overexpress HER2. Trastuzumab (Herceptin s ), a humanized monoclonal antibody reactive with HER2, has been an effective targeted therapy for patients with metastatic breast cancers that overexpress HER2 (Cobleigh et al., 1999; Finn and Slamon, 2003) .
Angiogenesis is required for the growth and progression of solid tumors and is mediated by both proangiogenic and antiangiogenic factors (Hanahan and Weinberg, 2000) . Vascular endothelial growth factor (VEGF) is one of most potent proangiogenic factors. VEGF not only stimulates endothelial cell proliferation and migration but also causes the degradation of the basement membrane in microvessel walls (Ferrara, 2002) . VEGF promotes the survival and invasiveness of breast cancer cells (Price et al., 2001; Harmey and Bouchier-Hayes, 2002) . Preclinical studies on cancer cell lines have revealed a tight relationship between HER2 signaling and VEGF expression (Petit et al., 1997; Pegram and Reese, 2002; Loureiro et al., 2005) . However, the signaling pathways that regulate VEGF expression remain controversial. The p21-activated kinase-1 (PAK-1), phosphatidylinositol 3 0 -kinase (PI3K), and mitogen-activated protein (MAP) kinases signaling pathways have all been implicated in the regulation of VEGF expression in breast cancer cells in different studies (Bagheri-Yarmand et al., 2000; Xiong et al., 2001; Chelouche-Lev et al., 2004) .
Interleukin-8 (IL-8) is a small CXC (two conserved cysteine residues separated by an additional amino acid residue) chemokine originally identified as a neutrophil chemotactic factor (Bar-Eli, 1999) . IL-8 was subsequently found to promote the growth and metastasis of tumors, in part by stimulating angiogenesis (Green et al., 1997; Bar-Eli, 1999; De Larco et al., 2001; Rofstad and halsor, 2002; Chen et al., 2003; Freund et al., 2003; Benoy et al., 2004) . Both tumor cells and tumorassociated neutrophils and macrophages have been reported to release IL-8, which contributes to accelerated tumor growth and poor survival (Chen et al., 2003) . The PI3K pathway has been implicated in regulation of IL-8 expression (Chelouche-Lev et al., 2004) . Hypoxia in solid tumors also stimulates the expression of both IL-8 and VEGF, and VEGF can further enhance IL-8 expression (Rofstad and Halsor, 2002) . IL-8 overexpression is associated with high metastatic potential in breast cancers (Green et al., 1997; De Larco et al., 2001; Freund et al., 2003) . IL-8 serum levels are increased in patients with breast cancers and are an independent prognostic factor for survival (Benoy et al., 2004) .
Thrombospondin 1 (TSP-1) is an antiangiogenic factor that can suppress tumor angiogenesis by inhibiting endothelial cell proliferation and by inducing endothelial cell apoptosis (Jimenez et al., 2000; Sargiannidou et al., 2001) . TSP-1 also inhibits the activity of matrix metalloproteinase-9 (MMP-9) (Ribatti et al., 1998; Rodriguez-Manzaneque et al., 2001) . TSP-1 inhibits angiogenesis by binding to the CD36 receptor protein, which is present on the endothelial cell surface (Dawson et al., 1997) . Low expression of TSP-1 expression has been associated with increased recurrence rates and decreased overall survival in human cancers (Sargiannidou et al., 2001) . The signaling pathways that regulate TSP-1 expression also remain controversial. MAP kinase signaling, including the activation of p38 and JNK, has been shown to regulate TSP-1 expression (Takekawa et al., 2002; Naito et al., 2004) , as has the PI3K pathway (Watnick et al., 2003) . HER2 signaling can affect TSP-1 expression in breast cancer. In an experimental model of human breast cancer, trastuzumab-induced normalization and regression of vasculature by modulating the expression of various pro-and antiangiogenic factors, including VEGF and TSP-1 (Izumi et al., 2002) . With the aid of small interfering RNA (siRNA) against HER2 (siHER2), our group has also observed that inhibition of HER2 by siHER2 upregulates TSP-1 expression (Yang et al., 2004) .
Although HER2 signaling has been shown to affect the expression of VEGF in breast cancer cells, the signaling pathways by which HER2 signaling modulates the expression of VEGF in tumor cells that overexpress HER2 and that might respond to trastuzumab therapy are still not defined. The effect of HER2 signaling on IL-8 and TSP-1 expression has not been studied, although there are reports that trastuzumab increases TSP-1 expression. Therefore, we overexpressed or inhibited HER2 function on the same genetic backgrounds to investigate the effects of HER2 signaling on VEGF, IL-8, and TSP-1 in vitro and in vivo. Our results confirmed that HER2 signaling regulates the expression of VEGF through the PI3K-AKT pathway in cancer cells that overexpress HER2. HER2 status significantly affected IL-8 expression in breast cancer cells, and HER2 signaling-regulated TSP-1 expression through the p38 pathway in cancer cells that overexpress HER2.
Results
Overexpression of HER2 stimulates cell proliferation and upregulates two proangiogenic factors, VEGF and IL-8 In order to test the role of HER2 signaling on angiogenesis, two breast cancer cell lines with low HER2 expression (MCF-7 and T-47D) were stably transfected with human HER2 cDNA to produce MCF-7/HER2 and T-47D/HER2 (Figure 1a ). Both MCF-7/ HER2 and T-47D/HER2 cells exhibited a higher rate of proliferation than their respective controls that contained empty vector (data not shown). Cell cycle analysis of these two pairs of cell lines showed that MCF-7/HER2 and T-47D/HER2 cells had a lower percentage of cells in the G1 phase of the cell cycle than did their respective control cells (data not shown). Accordingly, the cyclin-dependent kinase (CDK) inhibitor p27 kip1 was downregulated in MCF-7/HER2 and T-47D/HER2 cells, whereas CDK2 and cyclin D1 were upregulated in MCF-7/HER2 and T-47D/HER2 cells (data not shown). The effects of HER2 signaling on expression of angiogenic factors were then assessed in these isogenic breast cancer cell lines, which differed only in levels of HER2 expression. As shown in Figure 1b , the mRNA expression of VEGF was upregulated in MCF-7/HER2 cells, as revealed by duplex reverse transcritase-polymerase chain reaction (RT-PCR). The level of secreted VEGF in supernatants from MCF-7/HER2 cells was also increased, as shown by enzyme-linked immunosorbent assays (ELISA) (Figure 1c ). IL-8 expression in empty vector-transfected MCF-7 and T-47D cells was low (Figure 1d and e). The mRNA ( Figure 1d ) and protein ( Figure 1e ) expression of IL-8 was dramatically upregulated in MCF-7/HER2 and T-47D/HER2 cells.
Inhibition of HER2 signaling with trastuzumab or siHER2 downregualtes both VEGF and IL-8 expression in HER2-overexpressing cells Our data clearly indicated that induced HER2 overexpression in breast cancer cell lines stimulates VEGF and IL-8 expression and suppressed TSP-1 expression. We therefore next assessed the loss of HER2 function in breast cancer cells that endogenously overexpress HER2. HER2 signaling was downregulated trastuzumab or siHER2. As we have previously reported, trastuzumab specifically suppressed the tumor growth of breast cancer cells that overexpress HER2 through induction of G1 arrest associated with upregulation of the CDK inhibitor p27 kip1 and downregulation of CDK2 (Le et al., 2003 (Le et al., , 2005b . As shown in Figure 2a , trastuzumab treatment for 24 h did not affect the level of HER2 protein in BT474 cells, which overexpress HER2. As expected, trastuzumab significantly inhibited VEGF mRNA expression, as shown by duplex PCR (Figure 2b ). In addition to inhibiting VEGF, trastuzumab also inhibited IL-8 mRNA expression, in a timedependent manner (Figure 2b and c) . The inhibitory effect of trastuzumab on the expression of VEGF and IL-8 was further confirmed by ELISA analysis ( Figure  2d and e). siHER2 delivered by retrovirus has been shown to specifically affect HER2 signaling (Yang et al., 2004) . As expected, siHER2 diminished the level of HER2 protein (Figure 2a ). Similar to the effect of the anti-HER2 antibody trastuzumab, siHER2 downregulated both VEGF and IL-8 mRNA ( Figure 2b ) when compared with controls infected with empty vector (U6). siHER2 also inhibited the levels of VEGF and IL-8 protein secreted into supernatants of cell cultures (Figure 2d and e).
Overexpression of HER2 downregulates an antiangiogenic factor, TSP-1 Tumor angiogenesis is regulated by two sets of factors: proangiogenic and antiangiogenic factors. TSP-1 is an antiangiogenic factor in breast cancer. The effects of HER2 signaling on TSP-1 were assessed in the isogenic breast cancer cell lines by using duplex RT-PCR. As shown in Figure 3a , lower expression of TSP-1 was detected in MCF-7/HER2 cells than in cells transfected with vector alone. A modest reduction in TSP-1 was detected in T-47D/HER2 cells ( Figure 3a ). Northern blotting was used to confirm these findings. As shown in Figure 3b , both MCF-7/HER2 and T-47D/HER2 cells expressed dramatically less TSP-1 mRNA than cells transfected with empty vector.
Inhibition of HER2 signaling with trastuzumab or siHER2 upregualtes TSP-1 expression in HER2-overexpressing cells The effects of trastuzumab and siHER2 on antiangiogenic factor TSP-1 in breast cancer cells that overexpress HER2 were examined by Northern blotting. As expected, inhibition of HER2 with siHER2 upregulated TSP-1 expression (Figure 3c ). Trastuzumab also induced TSP-1 expression (Figure 3c ), and this induction (up to 8.8-fold) was dependent on antibody concentration ( Figure 3d ).
Trastuzumab inhibits tumor growth and vessel formation by downregulating VEGF and IL-8 expression and upregulating TSP-1 expression in vivo Our studies in cell culture showed that induced HER2 overexpression stimulated VEGF and IL-8 expression but suppressed TSP-1 expression, whereas blocking HER2 expression suppressed VEGF and IL-8 expression but stimulated TSP-1 expression. To determine whether trastuzumab has similar effects in vivo, we established BT474 xenografts in nu/nu mice. BT474 cells that overexpress HER2 (>10 6 copies per cell) were The PI3K-AKT pathway mediates HER2 signalingregulated VEGF and IL-8 expression Our results indicated that HER2 signaling regulated the expression of VEGF, IL-8 and TSP-1 in vitro and in vivo.
We next examined possible signaling pathways that could regulate expression of these angiogenic factors.
One was PI3K-AKT, which is important for HER2 signaling, and inhibition of HER2 signaling with trastuzumab significantly inhibits PI3K-AKT signaling (Le et al., 2000 (Le et al., , 2005a . It is also well documented that the PI3K-AKT pathway plays an important role in angiogenesis (Dimmeler and Zeiher, 2000; Jiang et al., 2000) . Therefore, we investigated the role of the PI3K-AKT pathway in regulating VEGF, IL-8, and TSP-1 expression. A PI3K inhibitor LY294002 was used in BT474 cells. As shown in Figure 5a , the mRNA levels of VEGF and IL-8 were downregulated in a concentrationdependent manner by LY294002, similar to the effect of trastuzumab (Figure 2 ). Secreted levels of VEGF and IL-8 protein were also significantly reduced by PI3K inhibition (Figure 5b ). Overexpression of HER2 in MCF-7 and T-47D cells increased the basal levels of phosphorylation of AKT at Serine 473 (Figure 5c ). Conversely, inhibition of HER2 function by siHER2 or trastuzumab decreased AKT phosphorylation (Figure 5c ). Similar to in vitro results, anti-HER2 antibody trastuzumab inhibited AKT phosphorylation in BT474 cells xenografts (Figure 5c ). To further characterize the specific effects of AKT on VEGF and IL-8, a stable subclone of SKBr3 cells that overexpress dominant-positive AKT1 was used to test the effect of AKT1 on the expression of VEGF and IL-8. As shown in Figure 5d , both VEGF and IL-8 levels were elevated 1.7-to 2.2-fold in AKT1-overexpressing cells compared with empty vector-transfected cells. Soluble VEGF (Figure 5e ) and IL-8 (Figure 5f ) levels in supernatants from AKT1-overexpressing cells increased even further. The overexpression of AKT1 in SKBr3 cells was evidenced by increasing in AKT Serine 473 phosphorylation (Figure 5g ). These results suggest that the PI3K-AKT pathway mediates HER2 signaling-associated VEGF and IL-8 expression.
The p38 MAP kinase pathway mediates HER2 signaling-regulated TSP-1 expression Interestingly, inhibiting the PI3K-AKT pathway did not affect TSP-1 expression: LY294002 had no effect on TSP-1 level in BT474 cells (Figure 6a ). Unlike overexpression of VEGF and IL-8, overexpression of AKT1 did not influence TSP-1 expression (Figure 6b ). These data suggest that a pathway or pathways other than PI3K-AKT regulate TSP-1 expression. Delayed activation of p38 mitogen-activated protein kinases (MAPK) has been reported to regulate TSP-1 expression in other cancer cell types (Takekawa et al., 2002; Naito et al., 2004) . Early activation of p38 kinase by the anti-HER2
antibody ID5 was reported previously (Le et al., 2000) . Therefore, we examined the role of p38 MAPK signaling in regulating TSP-1 expression in BT474 cells. As shown in Figure 6c , trastuzumab-induced upregulation of TSP-1 was blocked by the specific p38 MAPK inhibitor SB203580. To confirm the importance of the p38 MAPK pathway in regulating TSP-1 expression in HER2-overexpressing breast cancer cells, we transiently overexpressed an immediate upstream regulator of p38 kinase, MKK6, into MCF-7/HER2 cells. As shown in Figure 6d , p38 MAPK was activated, as expected. The TSP-1 mRNA level was dramatically increased in MKK6-transfected cells, as shown by Northern blotting (Figure 6d ). These data suggest that the p38 kinase pathway mediates HER2-induced regulation of TSP-1 expression in breast cancer cells. Indeed, overexpression of HER2 in MCF-7 and T-47D decreased the phosphorylation of p38 (Figure 6e ), whereas inhibition of HER2 by siHER2 or trastuzumab increased the p38 MAPK activity (Figure 6e ). Trastuzumab activated p38 MAPK over a prolonged period, starting 6 h after the treatment (Figure 6f ). Activation of p38 MAPK was also detected in trastuzumab-treated tumor samples from BT474 xenografts (Figure 6e ). Taken together, these results demonstrated that HER2 signaling regulates TSP-1 expression via the p38 MAPK pathway.
Discussion
In this study, we investigated the effect of activating and inhibiting HER2 signaling on two proangiogenic factors, VEGF and IL-8, and one antiangiogenic factor, TSP-1, in vitro and in vivo. Our results indicated that HER2 signaling regulates both pro-and antiangiogenic factors in breast cancer cells. Activation of HER2 signaling increased production of the proangiogenic factors (VEGF and IL-8) and decreased production of the antiangiogenic factor (TSP-1). Conversely, inhibition of HER2 signaling decreased production of VEGF and IL-8 and increased production of TSP-1. We also explored the signaling pathways by which HER2 regulates the angiogenic factors. HER2 overexpression stimulated both VEGF and IL-8 expression through the PI3K-AKT pathway but inhibited TSP-1 expression through the p38 MAP kinase pathway. We explored the molecular mechanisms by which the anti-HER2 antibody trastuzumab inhibits tumor angiogenesis and tumor growth. Trastuzumab has shown significant activity as a single agent in HER2-overexpressing metastatic breast cancers (Finn and Slamon, 2003) . Combination therapy with trastuzumab and microtubule-damaging taxanes dramatically increases the response rate, time to progression, and overall survival for patients with breast cancer when compared with chemotherapy alone (Finn and Slamon, 2003) . Trastuzumab also potentiates cytotoxic agents such as doxorubicin, gemcitabine, and vinorelbine (Nahta and Esteva, 2003; Baselga et al., 2004; Shahied et al., 2004; Stein et al., 2004) . Promising clinical results have also been reported using a combination of trastuzumab, docetaxel, and platinum (Crown and Pegram, 2003) . We have reported previously that arresting HER2-overexpressing cancer cells in the G1 phase of the cell cycle by induction of the CDK inhibitor p27 kip1 and reduction of CDK2 is one of the major mechanisms by which trastuzumab inhibits growth of cancer cells in vitro (Le et al., 2003 (Le et al., , 2005b . Antibody-dependent cellular cytotoxicity is one of major mechanisms by which anti-HER2 antibodies can exert cytotoxic effects in vivo. Bispecific antibodies against both HER2 receptor and the Fc gamma RIII-activating receptor are reported to have increased antibody-dependent cellular cytotoxicity (Shahied et al., 2004) . In this study, we found that trastuzumab markedly decreased expression of the proangiogenic factors VEGF and IL-8 through inhibition of the PI3K-AKT pathway. Concurrently, trastuzumab markedly increases expression of the antiangiogenic factor TSP-1 through activation of the p38 MAP kinase pathway. Trastuzumab changes the equilibrium between pro-and antiangiogenic factors in affected tumors and so inhibits tumor angiogenesis, which probably contributes to trastuzumab's antitumor activity in vivo and in vitro.
Anti-HER2 antibodies, including trastuzumab, have been reported to decrease VEGF expression in HER2-overexpressing cancer cells (Petit et al., 1997; Izumi et al., 2002; Klos et al., 2003; Spiridon et al., 2004) , which is further supported by our observations (Figure 2) . In this study, we found that inhibition of the PI3K-AKT pathway by trastuzumab contributed to VEGF downregulation ( Figure 5 ). To our knowledge, no correlation between HER2 function and IL-8 expression has been previously reported. Our data clearly show that HER2 signaling regulates IL-8 expression (Figures 1 and 2) . Trastuzumab inhibited IL-8 expression through inhibiting the PI3K-AKT pathway ( Figure 5 ). We also measured another proangiogenic factor, basic fibroblast growth factor, and its expression was not affected by trastuzumab treatment in cell culture (data not shown). TSP-1 is upregulated by trastuzumab treatment (Izumi et al., 2002) . HER2 siRNA treatment of HER2-overexpressing BT474 cells also increases TSP-1 expression (Yang et al., 2004) . Affymetrix microarray analysis indicated that treatment of BT474 cells with trastuzumab elevates TSP-1 expression (Le et al., 2005a) . In this report, we showed that HER2 signaling closely regulated TSP-1 expression (Figure 3) , which supports the notion that trastuzumab-induced TSP-1 expression (Figures 4 and 6 ) may contribute to tumor growth inhibition.
Elucidation of the signaling pathways by which trastuzumab regulates tumor-associated angiogenic factors may permit more direct targeting of these pathways in combination with trastuzumab treatment and so may lead to more potent and effective antivascular treatment for tumors that overexpress HER2. Trastuzumab only affects cancer cells that overexpress HER2. Normal cell components such as endothelial cells, pericytes, fibroblasts, and infiltrating leukocytes can also secrete various angiogenic factors that support tumor growth (Hanahan and Weinberg, 2000; Kumar and YarmandBagheri, 2001; Ferrara, 2002; Izumi et al., 2002) . Additional antiangiogenic agents that inhibit PI3K-AKT activity or stimulate p38 activity could target both cancer cells and other cell types by inhibiting the proangiogenic factors VEGF and IL-8 and by activating the antiangiogenic factor TSP-1. In pilot experiments, we have shown that trastuzumab and the PI3K inhibitor LY294002 have an additive effect on BT474 cell growth in cell culture (data not shown). Combination therapy with trastuzumab and a therapeutic molecule targeting VEGF and/or its receptors, such as the recombinant humanized monoclonal anti-VEGF antibody bevacizumab (Pegram and Reese, 2002; Miller et al., 2005) and VEGF-TRAP (Holash et al., 2002) , may prove active against HER2-overexpressing breast cancers.
One of the novel findings in this study is that IL-8 expression was dramatically increased in all HER2-overexpressing breast cancer cells (Figures 1, 2 and 4) . The importance of IL-8 as a proangiogenic factor has been documented in breast cancers (Green et al., 1997; De Larco et al., 2001; Freund et al., 2003; Sparmann and Bar-Sagi, 2004 ). Development of therapeutic molecules targeting IL-8 and/or human IL-8 receptors seems necessary for treatment of tumors that overexpress HER2, as we found a positive correlation between IL-8 expression and HER2 expression in this study.
We report for the first time that trastuzumab upregulated TSP-1 expression through a delayed but sustainable activation of the p38 MAP kinase pathway (Figure 6 ). In other cell systems, delayed activation of the p38 MAP kinase pathway also has a negative impact on cell proliferation by inducing apoptosis (Daly et al., 1999; Takekawa et al., 2002; Bulavin and Fornace, 2004; Naito et al., 2004) . Treatment of BT474 and SKBr3 cells with anti-HER2 antibodies for 72 h does not induce significant apoptosis (Le et al., 2003 (Le et al., , 2005a . Instead, trastuzumab-induced TSP-1 expression (Figures 3 and 4) , which was mediated by the delayed activation of p38 MAP kinase. Thus, delayed activation of p38 MAP kinase can inhibit cancer cell growth by two mechanisms: induction of apoptosis and inhibition of angiogenesis.
In the HER family, HER1/HER2 and HER2/HER3 heterodimers are most potent inducers of VEGF mRNA expression (Yen et al., 2002) . Two critical transcriptional factors, hypoxia-inducible factor 1 and Sp1, which are both involved in the PI3K-AKT pathway, have been shown to mediate the upregulation of VEGF by HER2 signaling (Yen et al., 2002; Loureiro et al., 2005) . Therefore, blocking the interaction of HER2 with HER1 by using an anti-EGFR antibody (Erbitux) and blocking the interaction of HER2 with HER3 by using anti-HER2 antibodies (trastuzumab or pertuzumab) seem to be a reasonable approach for antiangiogenic tumor therapy.
In summary, this study demonstrated that HER2 signaling mediates the equilibrium between pro-and antiangiogenic factors via two distinct signaling pathways. Trastuzumab inhibits angiogenesis and tumor growth by increasing p38 kinase-activated TSP-1 expression and by inhibiting PI3K-AKT-mediated IL-8 and VEGF expression.
Materials and methods
Cell culture T-47D and SKBr3 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and grown in complete medium containing RPMI 1640 (Media Preparation Core Facility, MD Anderson Cancer Center) supplemented with 10% fetal bovine serum (BSA, Sigma), 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin in humidified air with 5% CO 2 at 371C. BT474 (obtained from Dr Jose´Baselga, Vall d'Hebron University Hospital, Barcelona, Spain) and MCF-7 (ATCC) cells were grown in complete medium containing Dulbecco's modified Eagle's medium supplemented with 10% bovine serum albumin (BSA), 2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. For all experiments, cells were detached with 0.25% trypsin-0.02% ethylenediamine-N,N,N 0 , N 0 -tetraacetic acid (EDTA).
Reagents
Antibodies reactive with phospho-AKT (Ser-473), phosphop38 (Thr180/Try182), total AKT, and total p38 were obtained 
Transient and stable transfection
Parental MCF-7 and T-47D cells were transfected with an empty vector or the plasmid 9002 (obtained from Dr S McKenzie, Applied BioTechnology/Oncogene Science, Cambridge, MA, USA), which contains the full-length human HER2 gene. Transfection was facilitated with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) by following the manufacturer's instructions. Transfectants were selected with antibiotic G418 (800 mg/ml). Individual clones were picked, expanded, and assayed for HER2 expression by Western blotting. HER2-positive clones were then maintained in media with G418 (250 mg/ml). Similarly, flag-tagged MKK6 in pcDNA3.1 (obtained from Dr Han Jiahuai, Scripps Research Institute, La Jolla, CA, USA) was transiently transfected into MCF-7/HER2 cells. Cells were harvested 48 h later and subjected to Western or Northern blot analysis.
Cell proliferation assay
Cell proliferation assays were carried out using a nonradioactive cell proliferation kit (Promega, Madison, WI, USA) according to the manufacturer's protocol.
Retrovirus-mediated small interfering RNA against HER2 A BT474 clone that stably expressed siHER2 was established as described previously (Yang et al., 2004) .
Preparation of total protein and Western immunoblot analysis
Preparation of total protein from cell lines and Western blot analysis were performed as described previously (Le et al., 2003) . For extraction of whole lysates from tumor samples, tissues were harvested fresh, washed twice in 1 ml of PBS, and cut into small pieces with scissors or a razor. Tissue pieces were then homogenized in 1% Nonidet P 40 buffer (25 mM HEPESNaOH, pH 7.4, 150 mM NaCl, 4 mM EDTA, 1 mM dithiothreitol, 1% nonidet P 40, and 10% glycerol) containing protease inhibitors (50 mg/ml leupeptin, 10 mg/ml aprotinin, 10 mM pepstatin A, 1 mM phenylmethylsulfonyl fluoride in dimethyl sulfoxide) by grinding with a mortar and pestle at 41C. The homogenate was centrifuged at 12 000 r.p.m. for 15 min at 41C. The supernatants (whole lysates) were used for 6-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Generation of dominant-positive AKT1 stable transfectants SKBr3 subclones that stably express AKT1 were established as described previously (Le et al., 2005a) .
RT-PCR
Total RNA isolation and RT-PCR were performed according to the methods described previously (Le et al., 2005a) . One internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and one gene of interest (VEGF, IL-8 or TSP-1) were analysed in the same tube. Duplex PCR was carried out in 50 ml containing 0.25 mM of each primer, 0.05 mM of GAPDH, 100 mM dNTPs, Taq buffer, 50 ng of cDNA and 1U Taq 
Enzyme-linked immunosorbent assays
The levels of human VEGF and IL-8 in the supernatants obtained from BT474, MCF-7, or T-47D cells ( 10 6 ) with or without trastuzumab treatment were measured by Quantikine kits for human VEGF (catalog # DVEC00) and human IL-8 (catalog # D8000C) from R&D Systems (Minneapolis, MN, USA) according to the manufacturer's protocols. The levels of VEGF and IL-8 in each sample were expressed as picograms per 10 5 cells.
Northern blot analysis
Total RNA (12 mg) samples were denatured by heating to 651C for 3 min in a sample-loading buffer (1 Â Tris-Borate-EDTA (TBE), 6.5%. Ficoll, 0.005% bromphenol blue, 0.025% xylene cyanol FF, and 3.5 M urea). The samples were immediately chilled on ice and separated with 1% TBE buffered agarose gel for 3 h at 8 V/cm. RNA was then blotted overnight and UV crosslinked to Hybondt-N þ membrane (Amersham Pharmacia, Piscataway, NJ, USA). Prehybridization (30 min) and hybridization (overnight) were performed at 421C using ULTRAhybt buffer (Ambion, Austin, TX, USA). A 663 base pair TSP-1 probe was generated by RT-PCR (primer sequences shown in Materials and methods) and labeled with [a-32 P]dCTP (3000 Ci/mmol, Amersham Pharmacia, Arlington Heights, IL, USA) using the random primer method. After hybridization, the membrane was washed and exposed to X-ray film. The ethidium bromide (EB)-stained RNA gel was used to estimate the amount of RNA loaded.
BT474 xenografts in nude mice BT474 xenografts in nude mice were established according to Dr Jose Baselga's report (Baselga et al., 1998) . 10 7 BT474 breast cancer cells in 0.1 ml PBS were injected into two sites in the front mammary fat pads (mfp) of 4-to 6-week-old BALB/c athymic nu/nu mice (Harlan Sprague-Dawley, Houston, TX, USA). Seven mice per group were used for each treatment. Experiments with nu/nu mice were reviewed and approved by the MD Anderson Cancer Center -Institutional Animal Care and Use Committee (IACUC). All mice were maintained under specific pathogen-free conditions and given sterile food and water. A 17b-estradiol pellet (Innovative Research of America, Sarasota, FL, USA) was implanted as described previously (Le et al., 1998) . Once the tumors became palpable (mean size of 0.2-0.3 mm 3 at day 12 after injection), mice were divided into two groups and treated i.p. with trastuzumab (1 mg/kg) or hIgG (1 mg/kg) twice a week for 3 weeks. The tumors in hIgG-treated mice had reached the size limit set by IACUC at day 26 after injection of BT474 cells and all mice in this group were killed. Trastuzumab-treated mice were maintained for another week and killed. Tumors were collected immediately after killing for RNA and protein isolation, formalin fixation, or frozen in liquid nitrogen. Tumor sizes and body weights were measured twice a week by the same observer. The tumor volume in mm 3 was calculated as described previously (Le et al., 1998) . Experiments with nude mice were repeated three times with similar results.
Quantification of CD31-positive microvessel density Microvessel density was determined after immunohistochemical staining for CD31. Tumor samples resected from hIgG-or trastuzumab-treated mice were placed in Tissue-Tek OCT 4583 compound (Sakura, Torrance, CA, USA) and immediately flash-frozen in liquid nitrogen. All samples were stored at À701C until ready for use. Tumor sections were cut at 5 mm thickness from the frozen blocks with a Leica CM1850 minotome (Leica Microsystems, Wetzlar, Germany) set at À18 to À201C. Sections were fixed in cold acetone for 5 min and rinsed in PBS. Endogenous peroxidase was blocked by 3% H 2 O 2. After blocking in 5% serum for 30 min, the sections were incubated with anti-CD31 antibody (1:25 dilution) at 41C overnight. Sections were incubated with a biotinylated secondary antibody using an ABC kit (Labvision, Fremont, CA, USA) and developed with diaminobenzidine (Biogenex, San Ramon, CA, USA) by following the manufacturers' protocols. Microvessel density was quantified by counting the total number of CD31-positive vessels in six high-power fields ( Â 100). Images were collected with SlideBook software (Intelligent Imaging Innovations Inc., Denver, CO, USA) on a Nikon Optiphot microscope (Kanagawa, Japan) equipped with a Sony DXC-390 Camera (Sony, Tokyo, Japan).
IHC of VEGF, IL-8, and TSP-1 IHC was performed as described previously (Le et al., 2005a) . Specifically, the sections were incubated with anti-VEGF or anti-IL-8 antibodies at 1 mg/ml or anti-TSP-1 antibody at 4 mg/ ml overnight.
Statistical analysis
The two-tailed Student's t-test was used to compare different groups. Values with Po0.05 were considered statistically significant.
